Please Click the Issue to Download
Introduction
This resource provides insights from a medical oncologist who specializes in gastric cancer and esophageal cancer. Here you will find information on outcomes from Checkmate 649, a multicenter, randomized, phase 3, open-label study that evaluated OPDIVO plus capecitabine and oxaliplatin (CapeOX) or OPDIVO plus fluorouracil, leucovorin, and oxaliplatin (FOLFOX) compared with CapeOX or FOLFOX alone as first-line therapy in patients with previously untreated, unresectable, advanced or metastatic gastric cancer, gastroesophageal junction cancer, and esophageal adenocarcinoma without HER2-positive status and an Eastern Cooperative Oncology Group performance status of 0 or 1.